litlas
Log inCreate account

Kim Papp

Active 1999–2025

240
Papers
44,425
Citations
107
h-index
225
i10-index

Citations

Citations per year for Kim Papp1964: 1 citations1984: 1 citations1986: 1 citations1998: 10 citations2001: 2 citations2002: 10 citations2003: 52 citations2004: 48 citations2005: 80 citations2006: 99 citations2007: 136 citations2008: 138 citations2009: 200 citations2010: 185 citations2011: 247 citations2012: 275 citations2013: 359 citations2014: 345 citations2015: 386 citations2016: 469 citations2017: 714 citations2018: 697 citations2019: 1,970 citations2020: 1,970 citations2021: 1,895 citations2022: 1,565 citations2023: 1,586 citations2024: 1,956 citations2025: 1,121 citations2026: 9 citations1965–1983: no citations, so these years are not shown1985: no citations, so this year is not shown1987–1997: no citations, so these years are not shown1999–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,151 citing papers, 22.4% of this breakdownGermany: 1,124 citing papers, 8% of this breakdownUnited Kingdom: 1,003 citing papers, 7.1% of this breakdownCanada: 934 citing papers, 6.7% of this breakdownItaly: 810 citing papers, 5.8% of this breakdownChina: 716 citing papers, 5.1% of this breakdownFrance: 610 citing papers, 4.3% of this breakdownJapan: 561 citing papers, 4% of this breakdownSpain: 474 citing papers, 3.4% of this breakdownNetherlands: 448 citing papers, 3.2% of this breakdownSwitzerland: 438 citing papers, 3.1% of this breakdownDenmark: 344 citing papers, 2.5% of this breakdown
0%22.4%Other 24.4%

Institutions

Fields

  • Medicine49.4%
  • Immunology and Microbiology37.6%
  • Biochemistry, Genetics and Molecular Biology6.7%
  • Neuroscience3.7%
  • Pharmacology, Toxicology and Pharmaceutics0.9%
  • Psychology0.3%
  • Other1.4%

Topics

  • Psoriasis: Treatment and Pathogenesis16.5%
  • Dermatology and Skin Diseases12.9%
  • Spondyloarthritis Studies and Treatments7.4%
  • Asthma and respiratory diseases4%
  • Rheumatoid Arthritis Research and Therapies3.9%
  • Allergic Rhinitis and Sensitization3.4%
  • Other51.9%

Coauthors

All papers

Open in search
  1. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    Authors: Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, Jennifer Clay Cather, Jamie Weisman, David M. Pariser, Eric L. Simpson, Kim Papp, Hyuck-Ki Hong, Diana Rubel, Peter Foley, Errol P. Prens, C.E.M. Griffiths, Takafumi Etoh, Pedro Herranz, Ramón M. Pujol, Jacek C. Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Brad Shumel - The Lancet 2017 cited by 1,243

  2. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

    Authors: Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson, Kim Papp, Aileen L. Pangan, Andrew Blauvelt, Diamant Thaçi, Chia‐Yu Chu, Hyuck-Ki Hong, Norito Katoh, Amy S. Paller, Brian Calimlim, Yihua Gu, Xiaofei Hu, Meng Liu, Yang Yang, John Liu, Allan R. Tenorio, Alvina D. Chu, Alan D. Irvine - The Lancet 2021 cited by 543

  3. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

    Authors: April W. Armstrong, Melinda Gooderham, Richard B. Warren, Kim Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C. Szepietowski, Shinichi Imafuku, Elizabeth Colston, John Throup, Sudeep Kundu, Steve Schoenfeld, Misti Linaberry, Subhashis Banerjee, Andrew Blauvelt - Journal of the American Academy of Dermatology 2022 cited by 347

  4. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

    Authors: Richard G. Langley, Boni E. Elewski, Mark Lebwohl, Kristian Reich, C.E.M. Griffiths, Kim Papp, L. Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen‐Fang Tsai, Norman Wasel, Stephen K. Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, Alexander Karpov, Silvia Helou, C. Papavassilis - New England Journal of Medicine 2014 cited by 1,964

  5. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

    Authors: Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B. Gordon, Peter Foley, Phoebe Rich, C. Paul, Jerry Bagel, Elizabeth Colston, John Throup, Sudeep Kundu, Chitra Sekaran, Misti Linaberry, Subhashis Banerjee, Kim Papp - Journal of the American Academy of Dermatology 2022 cited by 279

  6. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

    Authors: Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, Shu Li, Alexa B. Kimball - Journal of the American Academy of Dermatology 2017 cited by 860

  7. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    Authors: Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, Richard G. Langley, Thomas A. Luger, Mamitaro Ohtsuki, Kristian Reich, David A. Amato, Susan Ball, Daniel Braun, Gregory S. Cameron, J. Erickson, Robert J. Konrad, Talia M. Muram, Brian J. Nickoloff, Olawale Osuntokun, Roberta J. Secrest, Fangyi Zhao, Lotus Mallbris, Craig L. Leonardi - New England Journal of Medicine 2016 cited by 838

  8. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

    Authors: Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez - The Lancet 2018 cited by 662

  9. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

    Authors: Alexa B. Kimball, Martin M. Okun, David Williams, Alice B. Gottlieb, Kim Papp, Christos C. Zouboulis, April W. Armstrong, Francisco A. Kerdel, Michael H. Gold, Seth Forman, Neil J. Korman, Evangelos J. Giamarellos‐Bourboulis, Jeffrey Crowley, Charles Lynde, Z. Reguiaï, Errol-Prospero Prens, Eihab Alwawi, Nael M. Mostafa, Brett Pinsky, Murali Sundaram, Yihua Gu, Dawn M. Carlson, Gregor B. E. Jemec - New England Journal of Medicine 2016 cited by 777

  10. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

    Authors: Kristian Reich, Kim Papp, Andrew Blauvelt, Stephen K. Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, N. Cichanowitz, Qing Li, Kenneth Liu, Carmen La Rosa, Stuart Green, Alexa B. Kimball - The Lancet 2017 cited by 556

  11. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

    Authors: Kristian Reich, Kim Papp, Andrew Blauvelt, Richard G. Langley, April W. Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Madden, Maggie Haitian Wang, Christopher L. Cioffi, Veerle Vanvoorden, Mark Lebwohl - The Lancet 2021 cited by 297

  12. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

    Authors: Kim Papp, Jacek C. Szepietowski, Leon Kircik, Darryl Toth, Lawrence F. Eichenfield, Donald Y.M. Leung, Seth Forman, May E. Venturanza, Kang Sun, Michael E. Kuligowski, Eric L. Simpson - Journal of the American Academy of Dermatology 2021 cited by 297

  13. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Authors: Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard G. Langley, ChiaChi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, C.E.M. Griffiths - Journal of the American Academy of Dermatology 2015 cited by 669

  14. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    Authors: Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula - New England Journal of Medicine 2015 cited by 806

  15. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

    Authors: Kim Papp, Kenneth B. Gordon, Diamant Thaçi, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab Girgis, Sudeep Kundu, Subhashis Banerjee - New England Journal of Medicine 2018 cited by 414

  16. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

    Authors: Emma Guttman‐Yassky, Diamant Thaçi, Aileen L. Pangan, Hwanhee Hong, Kim Papp, Kristian Reich, Lisa A. Beck, Mohamed‐Eslam F. Mohamed, Ahmed A. Othman, J. Anderson, Yihua Gu, Henrique D. Teixeira, Jonathan I. Silverberg - Journal of Allergy and Clinical Immunology 2019 cited by 357

  17. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

    Authors: Kim Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G. Krueger, J.‐P. Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen K. Tyring, B Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J. Padula - New England Journal of Medicine 2017 cited by 511

  18. Bimekizumab versus Adalimumab in Plaque Psoriasis

    Authors: Richard B. Warren, Andrew Blauvelt, Jerry Bagel, Kim Papp, Paul S. Yamauchi, April W. Armstrong, Richard G. Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher L. Cioffi, Luke Peterson, Nancy Cross, Kristian Reich - New England Journal of Medicine 2021 cited by 238

  19. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

    Authors: Craig L. Leonardi, Alexa B. Kimball, Kim Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T. Dooley, Kenneth B. Gordon - The Lancet 2008 cited by 1,865

  20. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis

    Authors: Mark Lebwohl, Linda Stein Gold, Bruce Strober, Kim Papp, April W. Armstrong, Jerry Bagel, Leon Kircik, Benjamin D. Ehst, Hwanhee Hong, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen C. Piscitelli, David S. Rubenstein, Philip M. Brown, Anna M. Tallman, Robert Bissonnette - New England Journal of Medicine 2021 cited by 178

  21. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

    Authors: Philip J. Mease, Apinya Lertratanakul, J. Anderson, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilová, Mauro Waldemar Keiserman, Xin Wang, Sheng Zhong, R. Mccaskill, Patrick Zueger, Aileen L. Pangan, William Tillett - Annals of the Rheumatic Diseases 2020 cited by 233

  22. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

    Authors: Eric L. Simpson, Kim Papp, Andrew Blauvelt, Chia‐Yu Chu, Hwanhee Hong, Norito Katoh, Brian Calimlim, Jacob P. Thyssen, Albert S. Chiou, Robert Bissonnette, Linda Stein Gold, Colleen Wegzyn, Xiaofei Hu, Meng Liu, John Liu, Allan R. Tenorio, Alvina D. Chu, Emma Guttman‐Yassky - JAMA Dermatology 2022 cited by 204

  23. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

    Authors: Kim Papp, Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich - The Lancet 2008 cited by 1,350

  24. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    Authors: C.E.M. Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, C. Paul, Alan Menter, Gregory S. Cameron, J. Erickson, Lu Zhang, Roberta J. Secrest, Susan Ball, Daniel Braun, Olawale Osuntokun, Michael Heffernan, Brian J. Nickoloff, Kim Papp - The Lancet 2015 cited by 831